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Introduction 
Methods 
• Solid tumours are characterised by a three-dimensional (3D) architecture that provides 
specific survival advantages such as resistance to anti-cancer drugs (Rios de la Rosa et 
al., 2018). 
• The expression of programmed death-ligand 1 (PD-L1) is one such survival mechanism 
employed by tumours to mediate immune evasion, drug resistance and tumour 
progression (Figure 1) (Dong et al., 2018). 
• PD-L1 overexpression by cancer cells and immune cells in the tumour microenvironment 
is well known to promote immune evasion, primarily by inhibition of cytotoxic T 
lymphocyte and natural killer (NK) cell effector function (Jiang et al., 2019). However, 
tumour-intrinsic PD-L1 signalling is less established. 
• Monoclonal antibodies targeting PD-L1 have demonstrated significant anti-tumour 
immune responses in select patients with advanced cancers (Yang and Hu, 2019) 
• Better mimicking of the 3D architecture of solid tumours by utilising 3D cell culture could 
provide an environment more representative of in vivo human tumours for the 
investigation of PD-L1 in relation to its tumour-intrinsic role, interaction with PD-1 on 
immune cells and response to treatment. 
Utilising 3D cell culture systems including the hanging drop method and alginate hydrogel beads, we have found that 
PD-L1 cell surface expression was altered consistently in both 3D cell culture methods in all the human cancer cell 
lines investigated with the exception of PC3 and SW480 cells in alginate when compared to their 2D counterparts. The 
level of expression of PD-L1 by cancer cells in 3D is more likely to mimic that of an in vivo human tumour 
microenvironment than standard 2D cell culture, and may better able the investigation of the tumour-intrinsic role of  
PD-L1, cancer cell-immune cell interactions and cancer cells response to PD-L1 targeted treatment. 
• This research aimed to determine whether the cell surface expression of PD-L1 was 
altered in human cancer cell lines when cultured in 3D as opposed to standard 2D cell 
culture.  
• It was hypothesised that human breast, prostate and colorectal cancer cell lines would 
express altered levels of cell surface PD-L1 in 3D cell culture compared to their 2D 
counterparts. 
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Aims and Hypothesis 
Figure 1. PD-L1/PD-1 signalling axis in cancer initiation and progression. PD-L1 binding to its receptor, PD-1 on T cells 
inhibits T cell activation by interfering with the T cell receptor (TCR) signal transduction via the recruitment of SHP1 and 
SHP2, leading to T cell anergy or apoptosis, supressing anti-tumour immunity. PD-1 is also expressed by other immune 
cells such as NK cells and B cells. In select cancer types, there is a potential emerging role of PD-L1 signalling in cancer 
cells. PD-L1 signalling in some cancer cells has been shown to promote cancer cell stemness, epithelial to mesenchymal 
transition (EMT), invasion, metastasis, drug resistance and regulate glucose metabolism (Dong et al., 2018).  
Cell culture  Human cancer cell lines were cultured in RPMI (MDA-MB-231, MCF-7, LNCaP 
and PC3) or DMEM (SW480 and SW620) media supplemented with 10% FBS and 1% 
penicillin-streptomycin. Cells were cultured in 2D and 3D; two well-established 3D cell culture 
systems were utilised (Figure 2). All cell lines were purchased from ATCC, frequently tested 
for mycoplasma and were below passage 30 for all experiments. 
Cell viability in 3D spheroids At specific time points a single alginate bead or spheroid for 
each cell line was harvested, placed in a 96-well plate and labelled with Hoechst 33342 (10 
µg/mL) and propidium iodide (PI) (10 µg/mL). Images were captured using cellSense 
Software on an Olympus IX81 microscope. 
Cell surface staining Human cancer cell lines growing in 3D spheroids and their monolayer 
counterparts were stained with fluorescently labelled anti-human PD-L1 and matched isotype 
control. PD-L1 cell surface expression was assessed using flow cytometry and data was 
analysed using FlowJo software. The median fluorescent intensity (MFI) was normalised 
relative to the isotype control and appropriate gating of single and live cells was carried out 
for each experiment. 
Figure 2. A schematic diagram of the work flow applied to investigate human cancer cell PD-L1 cell surface 
expression in 2D versus 3D using two well-established 3D cell culture systems. Human breast, prostate and 
colorectal cancer cell lines were grown in 2D and 3D cell culture for investigating PD-L1 cell surface expression. For 3D cell 
culture, the hanging drop method and alginate hydrogel beads were utilised which facilitate the formation of spheroids that 
display heterogeneous population of cells resembling that found in the tumour microenvironment. Spheroids generated were 
harvested for microscopic and flow cytometric analysis at day 3 from hanging drop and day 3, day 6 and day 10 from 
alginate hydrogel beads. 
Figure 4. Human breast, prostate and colorectal cancer cell spheroids generated using the hanging drop method display altered PD-L1 expression 
when compared to their 2D counterparts at day 3. MDA-MB-231 cancer cells exhibit a significant decrease in the level of PD-L1 expression at day 3 (A). 
MCF-7 (B), LNCaP (C), SW480 (E) and SW620 (F) cancer cells display a significant increase in PD-L1 expression at day 3. LNCaP and SW480 also display 
an increase in the level of PD-L1 expression at day 3. PC3 cancer cells show a significant decrease in PD-L1 but display no change in the level of PD-L1 
expression at day 3 (D). Representative flow cytometry plots are displayed for each cell line showing the isotype control (grey) relative to the PD-L1 positive 
populations for cells grown in 2D (orange) and 3D (pink). The PD-L1 percentage expression is graphed alongside the normalised MFI.  Data is presented as 
mean ± SD, n=3 independent experiments each with 3 technical repeats, Mann-Whitney U test, *P<0.05.  
Figure 3. Human breast, prostate and colorectal cancer cell lines form viable and intact spheroids. Single spheroids generated by hanging drop were 
harvested at day 3 for viability assessment using Hoechst 33342/PI staining. MCF-7 (A), LNCaP (B), PC3 (C), SW480 (D) and SW620 (E) cancer cells form 
viable and intact spheroids at day 3 in hanging drop. MDA-MB-231 cancer cells disaggregate upon harvesting from the petri dish lid. Day 3 viability for MDA-
MB-231 cancer cells was assessed by flow cytometry. Scale bar represents 100 μm.  










Figure 5. Human cancer cell 
spheroids formed in alginate 
hydrogel beads exhibit altered PD-L1 
expression in comparison to their 2D 
counterparts. Fluorescent images 
obtained by Hoechst 33342/PI staining 
of whole intact alginate beads at day 10 
are shown for each cell line. Scale bar 
represents 500 μm. The closer images 
of individual spheroids in the white 
boxes represent spheroids within the 
alginate bead that have a diameter of 
100-200 μm for each cell line. MDA-
MB-231 cancer cells grown in 3D 
alginate display a significant decrease 
in PD-L1 expression over time 
compared to when grown in 2D (A). 
MCF-7 cancer cells show a significant 
increase in PD-L1 expression at each 
time point investigated in 3D in 
comparison to their 2D counterparts 
(B). LNCaP cancer cells show a trend 
increase in PD-L1 expression at each 
time point in 3D compared to in 2D 
monolayer. LNCaP PD-L1 expression is 
significant in 3D at day 6 (C). PC3 (D) 
and SW480 (E) cancer cells grown in 
3D alginate exhibit no change in PD-L1 
expression compared to their 2D 
counterparts at each time point 
investigated. SW620 cancer cells 
grown in 3D alginate display a 
significant increase in PD-L1 
expression at day 3 and day 10 
compared to when grown in 2D 
monolayer (F). Representative flow 
cytometry plots are displayed for each 
cell line showing the isotype control 
(grey) relative to the PD-L1 positive 
populations for cells grown in 2D 
(orange) and 3D (pink). The PD-L1 
percentage expression is graphed 
alongside the normalised MFI.  Data is 
presented as mean ± SD, n=3 
independent experiments each with 3 
technical repeats, Two-way ANOVA, 
non-significant (ns), *P<0.05, **0.01, 
****P<0.0001.  
